Tenax Therapeutics Appoints Highly Experienced CFO with Substantial Equity Inducement

summarizeSummary

Tenax Therapeutics has appointed Thomas R. Staab, II, an experienced healthcare finance executive, as its new Chief Financial Officer, effective May 11, 2026, accompanied by a significant equity inducement package.

check_boxKey Events

• New Chief Financial Officer Appointed

  Tenax Therapeutics announced the appointment of Thomas R. Staab, II as its new Chief Financial Officer, effective May 11, 2026.

• Experienced Healthcare Finance Leader Joins

  Mr. Staab brings over 25 years of financial and executive experience in the healthcare industry, including prior CFO roles at LENSAR, BioCryst Pharmaceuticals, and Inspire Pharmaceuticals.

• Significant Inducement Equity Awards Granted

  As part of his compensation, Mr. Staab will receive 10,000 restricted stock units and options to purchase 450,000 shares of common stock, approved under Nasdaq Listing Rule 5635(c)(4).

• Interim CFO Transition

  Thomas A. McGauley will step down as Interim CFO on May 10, 2026, but will continue as principal financial and accounting officer until the upcoming 10-Q filing to ensure a smooth transition.

auto_awesomeAnalysis

The appointment of Thomas R. Staab, II as Chief Financial Officer is a highly significant development for Tenax Therapeutics, a Phase 3 development-stage pharmaceutical company. Mr. Staab's extensive background, including CFO roles at multiple publicly-traded healthcare companies and experience with M&A, is crucial for a company navigating late-stage clinical trials and preparing for potential commercialization. His expertise will be vital in managing the company's financial strategy, securing future capital, and optimizing operations, especially given the previously reported widened net loss and increased R&D expenses. The substantial equity inducement awards, while dilutive, underscore the company's commitment to attracting top-tier talent essential for its strategic growth and long-term success. This leadership change strengthens the company's financial stewardship at a critical juncture.